August 14, 2025 — Predictive Oncology (Nasdaq: POAI) reported its financial and operating results for the quarter ended June 30, 2025, with a loss from continuing operations of approximately $2.0 million.
The company is advancing preparations for market expansion of its ChemoFx assay in the U.S. and Europe. ChemoFx tests chemotherapies on patient cancer cells to determine effectiveness. The company also developed 3D liver toxicity models for Labcorp and identified promising drug repurposing candidates using abandoned drug datasets.
Predictive Oncology announced a standby equity purchase agreement for up to $10 million with YA II PN, LTD.
The company concluded the quarter with $506,078 in cash and cash equivalents. Basic and diluted loss per common share from continuing operations was $0.22.
The company recorded revenue of $2,682 for the quarter. General and administrative expenses increased, while operations, research and development expenses decreased. Sales and marketing expenses increased.
Net cash used in operating activities was $4,280,632 for the six months ended June 30, 2025.
Michael Moyer, LifeSci Advisors, LLC, mmoyer@lifesciadvisors.com
Source: Predictive Oncology
